Literature DB >> 29129716

The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.

George M Burslem1, Blake E Smith1, Ashton C Lai1, Saul Jaime-Figueroa1, Daniel C McQuaid1, Daniel P Bondeson1, Momar Toure1, Hanqing Dong2, Yimin Qian2, Jing Wang2, Andrew P Crew2, John Hines1, Craig M Crews3.   

Abstract

Proteolysis targeting chimera (PROTAC) technology has emerged over the last two decades as a powerful tool for targeted degradation of endogenous proteins. Herein we describe the development of PROTACs for receptor tyrosine kinases, a protein family yet to be targeted for induced protein degradation. The use of VHL-recruiting PROTACs against this protein family reveals several advantages of degradation over inhibition alone: direct comparisons of fully functional, target-degrading PROTACs with target-inhibiting variants that contain an inactivated E3 ligase-recruiting ligand show that degradation leads to more potent inhibition of cell proliferation and a more durable and sustained downstream signaling response, and thus addresses the kinome rewiring challenge seen with many receptor tyrosine kinase inhibitors. Combined, these findings demonstrate the ability to target receptor tyrosine kinases for degradation using the PROTAC technology and outline the advantages of this degradation-based approach.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  EGFR; HER2; PROTAC; VHL; c-Met; receptor tyrosine kinases; targeted degradation

Mesh:

Substances:

Year:  2017        PMID: 29129716      PMCID: PMC5831399          DOI: 10.1016/j.chembiol.2017.09.009

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  63 in total

1.  A direct role for Met endocytosis in tumorigenesis.

Authors:  Carine Joffre; Rachel Barrow; Ludovic Ménard; Véronique Calleja; Ian R Hart; Stéphanie Kermorgant
Journal:  Nat Cell Biol       Date:  2011-06-05       Impact factor: 28.824

2.  Selective Downregulation of JAK2 and JAK3 by an ATP-Competitive pan-JAK Inhibitor.

Authors:  S Denise Field; Jacob Arkin; Jing Li; Lyn H Jones
Journal:  ACS Chem Biol       Date:  2017-03-22       Impact factor: 5.100

3.  Chemical biology: Greasy tags for protein removal.

Authors:  Taavi K Neklesa; Craig M Crews
Journal:  Nature       Date:  2012-07-18       Impact factor: 49.962

4.  A comprehensive mathematical model for three-body binding equilibria.

Authors:  Eugene F Douglass; Chad J Miller; Gerson Sparer; Harold Shapiro; David A Spiegel
Journal:  J Am Chem Soc       Date:  2013-04-16       Impact factor: 15.419

Review 5.  Cell signaling by receptor tyrosine kinases.

Authors:  Mark A Lemmon; Joseph Schlessinger
Journal:  Cell       Date:  2010-06-25       Impact factor: 41.582

6.  Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.

Authors:  Marianela Perez-Torres; Marta Guix; Adriana Gonzalez; Carlos L Arteaga
Journal:  J Biol Chem       Date:  2006-11-01       Impact factor: 5.157

7.  Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.

Authors:  Alison M Kurimchak; Claude Shelton; Kelly E Duncan; Katherine J Johnson; Jennifer Brown; Shane O'Brien; Rashid Gabbasov; Lauren S Fink; Yuesheng Li; Nicole Lounsbury; Magid Abou-Gharbia; Wayne E Childers; Denise C Connolly; Jonathan Chernoff; Jeffrey R Peterson; James S Duncan
Journal:  Cell Rep       Date:  2016-07-21       Impact factor: 9.423

8.  Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.

Authors:  Flavio Solca; Goeran Dahl; Andreas Zoephel; Gerd Bader; Michael Sanderson; Christian Klein; Oliver Kraemer; Frank Himmelsbach; Eric Haaksma; Guenther R Adolf
Journal:  J Pharmacol Exp Ther       Date:  2012-08-10       Impact factor: 4.030

9.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Authors:  Teresa A Soucy; Peter G Smith; Michael A Milhollen; Allison J Berger; James M Gavin; Sharmila Adhikari; James E Brownell; Kristine E Burke; David P Cardin; Stephen Critchley; Courtney A Cullis; Amanda Doucette; James J Garnsey; Jeffrey L Gaulin; Rachel E Gershman; Anna R Lublinsky; Alice McDonald; Hirotake Mizutani; Usha Narayanan; Edward J Olhava; Stephane Peluso; Mansoureh Rezaei; Michael D Sintchak; Tina Talreja; Michael P Thomas; Tary Traore; Stepan Vyskocil; Gabriel S Weatherhead; Jie Yu; Julie Zhang; Lawrence R Dick; Christopher F Claiborne; Mark Rolfe; Joseph B Bolen; Steven P Langston
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

10.  Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.

Authors:  Bing Zhou; Jiantao Hu; Fuming Xu; Zhuo Chen; Longchuan Bai; Ester Fernandez-Salas; Mei Lin; Liu Liu; Chao-Yie Yang; Yujun Zhao; Donna McEachern; Sally Przybranowski; Bo Wen; Duxin Sun; Shaomeng Wang
Journal:  J Med Chem       Date:  2017-03-24       Impact factor: 7.446

View more
  133 in total

Review 1.  Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective.

Authors:  Xinrui Yang; He Yin; Richard D Kim; Jason B Fleming; Hao Xie
Journal:  Target Oncol       Date:  2020-12-28       Impact factor: 4.493

2.  Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).

Authors:  Chengwei Zhang; Xiao-Ran Han; Xiaobao Yang; Biao Jiang; Jing Liu; Yue Xiong; Jian Jin
Journal:  Eur J Med Chem       Date:  2018-03-27       Impact factor: 6.514

Review 3.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

Review 4.  Advances in targeting 'undruggable' transcription factors with small molecules.

Authors:  Matthew J Henley; Angela N Koehler
Journal:  Nat Rev Drug Discov       Date:  2021-05-18       Impact factor: 84.694

Review 5.  The PROTACtable genome.

Authors:  Melanie Schneider; Chris J Radoux; Andrew Hercules; David Ochoa; Ian Dunham; Lykourgos-Panagiotis Zalmas; Gerhard Hessler; Sven Ruf; Veerabahu Shanmugasundaram; Michael M Hann; Pam J Thomas; Markus A Queisser; Andrew B Benowitz; Kris Brown; Andrew R Leach
Journal:  Nat Rev Drug Discov       Date:  2021-07-20       Impact factor: 84.694

6.  Exploiting Ubiquitin Ligases for Induced Target Degradation as an Antiviral Strategy.

Authors:  Rati Verma
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay.

Authors:  Caroline A Foley; Frances Potjewyd; Kelsey N Lamb; Lindsey I James; Stephen V Frye
Journal:  ACS Chem Biol       Date:  2019-12-27       Impact factor: 5.100

Review 8.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

9.  An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells.

Authors:  Ekaterina V Vinogradova; Xiaoyu Zhang; David Remillard; Daniel C Lazar; Radu M Suciu; Yujia Wang; Giulia Bianco; Yu Yamashita; Vincent M Crowley; Michael A Schafroth; Minoru Yokoyama; David B Konrad; Kenneth M Lum; Gabriel M Simon; Esther K Kemper; Michael R Lazear; Sifei Yin; Megan M Blewett; Melissa M Dix; Nhan Nguyen; Maxim N Shokhirev; Emily N Chin; Luke L Lairson; Bruno Melillo; Stuart L Schreiber; Stefano Forli; John R Teijaro; Benjamin F Cravatt
Journal:  Cell       Date:  2020-07-29       Impact factor: 41.582

10.  Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.

Authors:  Ka Yang; Hao Wu; Zhongrui Zhang; Eric D Leisten; Xueqing Nie; Binkai Liu; Zhi Wen; Jing Zhang; Michael D Cunningham; Weiping Tang
Journal:  ACS Med Chem Lett       Date:  2020-03-18       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.